I read with interest the manuscript by Indes and colleagues[@bib1] regarding the arterial complications in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work adds to the growing body of literature on this unique viral complication. COVID-19-associated coagulopathy is associated with elevated fibrinogen, D-dimer, and c-reactive protein (CRP); some centers have described higher-than-expected rates of venous thromboembolism.[@bib2] Markedly elevated D-dimer levels have also been reported as being associated with severe COVID-19 infections and mortality.[@bib2] ^,^ [@bib3] Proposed hypotheses to explain the venous thrombosis in COVID-19 center on a dysregulated inflammatory response manifesting as cytokine storm, complement activation, and endothelial injury.[@bib4] ^,^ [@bib5] The observation of increased risk of venous thrombosis in association with severe illness due to viral infections in itself is not novel; whether (and to what degree) severe COVID-19 infection is associated with a uniquely pro-thrombotic phenotype remains uncertain.

Whereas venous thromboembolism has been reported in previous outbreaks of coronaviruses, including SARS-CoV-1 and Middle-Eastern respiratory syndrome (MERS-CoV), as well as influenza A H1N1 acute respiratory distress syndrome[@bib6] ^,^ [@bib7], the association between SARS Co-V2 infection and arterial thrombosis has not been reported with other viral infections. The coagulopathy observed in COVID-19 is different from the disseminated intravascular coagulopathy (DIC) typically seen in sepsis. Specifically, the associated thrombocytopenia and prolonged aPTT and/or PT are mild.[@bib4] This observation lead to speculation that the arterial thrombosis is a direct result of SARS-CoV-2 infection of endothelial cells through the Angiotensin-converting enzyme 2 (ACE2) receptor and subsequent endotheliitis.[@bib5] ^,^ [@bib9] Also intriguing, is the unpredictable nature of this arterial thrombosis among patients infected with COVID-19. Indes et al and others observed no correlation between COVID-19 disease severity and the degree of arterial thrombosis^,^ while others observed the arterial thrombosis in the severely ill patients.[@bib1] ^,^ [@bib8] ^,^ [@bib9] This is not unusual as reports of rare disease entities can appear seemingly contradictory especially in the early phases of understanding a disease process. However, these observations can also suggest that perhaps the underlying mechanism of COVID-19-associated arterial thrombosis is independent of the cytokine storm seen in patients with COVID-19 associated venous thrombosis.

The growing experience with COVID-19-associated arterial thrombosis raises the question of the optimal dose of heparin anticoagulation for patients with COVID-19 infection and if there is a role for prophylactic antiplatelet therapy. Variable protocols have been proposed at the local institutional levels to address this concern. Ultimately, the optimal management will continue to evolve as we continue to gain insight into the pathophysiology of COVID-19.[@bib10] I look forward to learning from the growing body of data via multicenter collaborations such as the Vascular Surgery COVID-19 Collaborative (VASCC) and the numerous observational trials on thrombosis in patients with COVID-19.[@bib7] Should the pandemic continue, way may also need to consider well designed randomized trials to determine which patients are at risk for arterial events and how best to prevent them. Meanwhile, we need to remain vigilant to the risk of COVID-19-associated arterial thrombosis and to act expeditiously to recognize and treat this complication when it does occur.
